CME Group Inc (CME)
Official siteFINANCIAL SERVICES • FINANCIAL DATA & STOCK EXCHANGES • NASDAQ
Market Cap: $113.81B
Last updated: Nov 17, 2026 at 11:05 AM ET
CME Group Inc (CME) Stock Forecast
Analysts expect CME Group (CME) to earn $12.40 per share in the fiscal year ending Dec 31, 2026, on revenue of $7.09B. Of 17 analysts, 9 rate the stock Buy or Strong Buy, 6 Hold and 2 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 13 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 17 ratings average 2.35, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 53% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 5 | 29.4% |
| Buy | 4 | 23.5% |
| Hold | 6 | 35.3% |
| Sell | 1 | 5.9% |
| Strong Sell | 1 | 5.9% |
- Consensus
- Buy
- Total analysts
- 17
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 6.9% and revenue estimates rise 5.4%.
- Fiscal year ending Dec 31, 2026
- $12.40
- EPS consensus, revenue $7.09B
- Fiscal year ending Dec 31, 2027
- $13.25
- EPS consensus, revenue $7.47B
- Next report
- Feb 2, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $12.40 | $12.29 to $12.66 | 17 | $7.09B | $7.04B to $7.13B | 14 |
| Dec 31, 2027 | $13.25 | $12.38 to $13.70 | 17 | $7.47B | $7.11B to $7.74B | 14 |
Quarterly Estimates
The EPS consensus rises from $3.06 for the quarter ending Dec 31, 2026 to $3.32 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $3.06 | $2.86 to $3.44 | 16 | $1.79B | $1.69B to $1.97B | 15 |
| Mar 31, 2027 | $3.32 | $3.05 to $3.60 | 12 | $1.86B | $1.73B to $1.97B | 8 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 33 upward and 6 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 13 | 1 |
| Fiscal year ending Dec 31, 2027 | 13 | 1 |
| Quarter ending Mar 31, 2027 | 7 | 4 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 1.1% from $12.27.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $12.40 | $12.40 | $12.30 | $12.25 | $12.27 | +1.1% |
| Fiscal year ending Dec 31, 2027 | $13.25 | $13.23 | $12.99 | $12.93 | $12.93 | +2.4% |
| Quarter ending Mar 31, 2027 | $3.32 | $3.30 | $3.28 | $3.29 | $3.29 | +1.1% |
Frequently Asked Questions About CME
What is the CME stock forecast?
Consensus analyst estimates put CME Group's EPS at $12.40 for the fiscal year ending Dec 31, 2026, on revenue of $7.09B. The consensus rating from 17 analysts is Buy.
How do analysts rate CME stock?
Of 17 analysts covering CME Group, 5 rate it Strong Buy, 4 Buy, 6 Hold, 1 Sell and 1 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CME next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $12.40, with estimates from $12.29 to $12.66 from 17 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $13.25, with estimates from $12.38 to $13.70 from 17 analysts.
What revenue do analysts expect from CME Group next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $7.09B, with estimates from $7.04B to $7.13B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $7.47B, with estimates from $7.11B to $7.74B.
How many analysts cover CME?
17 analysts rate CME Group stock, and 17 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CME pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors